Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures Ended

2023-506823-28-00 Adult patients with locally advanced/metastatic solid t 4 2024-06-14
EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer Ended

2023-509336-25-00 Metastatic castration-resistant prostate cancer 9 2024-06-12
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined with Atezolizumab in Non-Hodgkin's … Ended

2023-506820-10-00 B-Cell Malignancies 9 2024-06-11
Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended

2023-505712-37-00 The participants must have a histologically confirmed d 10 2024-06-06
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col… Ended

2023-509771-17-00 Metastatic Colorectal cancer (mCRC) 10 2024-06-04
Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms. Ended

2023-507781-13-00 Patients with relapsed/refractory acute myeloid leukemi 1 2024-05-24
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended

2023-507324-23-00 recurrent or persistent uterine serous carcinoma 4 2024-05-22
[68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma Ended

2022-500918-25-00 Marginal Zone Lymphoma 5 2024-05-20
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Pat… Ended

2023-506976-28-00 Relapsed and/or Refractory CD20-expressing Non-Hodgkin 9 2024-05-16
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-… Ended

2023-506881-30-00 Melanoma 3 2024-05-15
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ended

2024-510877-67-00 Phase I:Adult patients with centrally confirmed diagnos 8 2024-05-14
A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional con… Ended

2024-512954-96-00 Glioblastoma 9 2024-05-14
A First in Human open label study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-Tumor Activi… Ended

2023-508386-32-00 Hematologic tumors 1 2024-05-10
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination W… Ended

2023-508124-36-00 Advanced or metastatic breast cancer and other advanced 1 2024-05-10
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended

2023-503223-26-00 Advanced Solid Tumors Harboring a KRASG12C Mutation 9 2024-05-07
BIOMarkers in Endometrial Cancer - A phase III open label randomized trial to determine the efficacy of biomarker staging as compared to con… Ended

2023-505991-31-00 ENDOMETRIAL CANCER 5 2024-04-30
First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended

2023-504012-16-00 Unresectable Locally Advanced or Metastatic Cancer 7 2024-04-29
Phase 1/1b Multiple-Ascending Dose Study of DF6215 in Patients With Advanced Solid Tumors Ended

2023-507320-23-00 Advanced Solid Tumors 1 2024-04-26
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Ended

2023-504630-22-00 Non-Small Cell Lung Cancer 7 2024-04-19
"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-nega… Ended

2022-501507-27-00 Advanced or metastatic triple-negative breast cancer 4 2024-04-17
Trial to assess the safety and preliminary efficacy of GEN1055 on malignant solid tumors as monotherapy and as combination therapy. Ended

2023-507049-28-00 Malignant Solid Tumors 7 2024-04-16
A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos… Ended

2023-506038-65-00 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METAS 4 2024-04-15
A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors Ended

2022-500823-61-00 Advanced Solid Tumours 7 2024-04-08